By Fineline Cube 
Korean AI drug discovery company Dr. Noah Biotech has announced the initiation of discussions with Thermo Fisher Scientific regarding a potential strategic collaboration aimed at accelerating the development of treatments for rare diseases. This partnership would combine Dr. Noah’s proprietary AI drug discovery platform, “ARK”, with Thermo Fisher’s AI-driven formulation technology “Quadrant 2” and its expertise in organoid model development.
Collaboration Details
The collaboration seeks to integrate Dr. Noah’s ARK platform and Thermo Fisher’s Quadrant 2 technology to address unmet medical needs in rare diseases. By leveraging these advanced AI capabilities, the companies aim to enhance the efficiency of drug development and improve outcomes for patients.
Development Process
Under the proposed framework, Dr. Noah’s ARK platform will design promising combination drug candidates within months. Subsequently, these candidates will undergo precise efficacy and toxicity testing in patient-derived organoid models provided by Thermo Fisher. This approach aims to streamline the drug development process and increase the likelihood of successful treatments reaching patients faster.-Fineline Info & Tech